All Outputs (2)

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia (2024)
Journal Article
Greiner, J., Mohamed, E., Fletcher, D. M., Schuler, P. J., Schrezenmeier, H., Götz, M., & Guinn, B.-A. (2024). Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia. Cancers, 16(20), Article 3443. https://doi.org/10.3390/cancers16203443

Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid progenitor cells. Nucleophosmin 1 (NPM1) gene mutations are the most common genetic abnorm... Read More about Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.

Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer? (2024)
Journal Article
Mohamed, E., Fletcher, D., Hart, S., & Guinn, B.-A. (2024). Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?. Onco, 4(2), 87-100. https://doi.org/10.3390/onco4020008

Lung cancer (LC) is one of the leading causes of cancer-related deaths. Pulmonary nodules are one of the risk factors and their discovery rate has been increasing due to enhanced performance of chest CT scans but more than 90% are non-malignant causi... Read More about Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?.